Roche Aktie

335,55 EUR -3,35 EUR -0,99 %

15:32:16

FSE

310,20 CHF +3,50 CHF +1,14 %

16:40:34

SWX

Roche jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 11/2024)

Jetzt loslegen

Direkt handeln

Bei einem anderen Broker handeln

Marktkap.247,01 Mrd. EUR

KGV24,60Div. Rendite3,80%

WKN855167

ISINCH0012032048

SymbolRHHVF

Roche Aktien News

Sortieren:Datum Meistgelesen

08.10.24PR NewswireSurvey commissioned by Roche shows that HPV infection, which causes 99% of all cervical cancer cases, remains largely misunderstood by the general public

26.09.24GlobeNewswirePositive phase III results for Roche’s Gazyva/Gazyvaro show superiority to standard therapy alone in people with lupus nephritis

24.09.24GlobeNewswireRoche launches the first test to use its breakthrough TAGS technology for high throughput, simultaneous detection of 12 respiratory viruses

23.09.24GlobeNewswireWHO endorses dual-stain cytology (CINtec PLUS) testing in its cervical cancer prevention guidelines, advancing patient care and underlining Roche’s role in pioneering cervical cancer solutions

19.09.24GlobeNewswirePositive phase III results show Xofluza significantly reduces the transmission of influenza viruses

16.09.24GlobeNewswireFDA approves OCREVUS ZUNOVO™ as the first and only twice-a-year 10-minute subcutaneous injection for people with relapsing and progressive multiple sclerosis

13.09.24GlobeNewswireFDA approves Roche’s Tecentriq Hybreza, the first and only subcutaneous anti-PD-(L)1 cancer immunotherapy

10.09.24GlobeNewswireRoche opens Pharma Research and Development Center in Basel to accelerate scientific innovation

10.09.24GlobeNewswireRoche eröffnet Pharmaforschungs- und Entwicklungszentrum in Basel, um wissenschaftliche Innovationen zu beschleunigen

09.09.24PR NewswireRoche advances AI-driven cancer diagnostics by expanding its digital pathology open environment

04.09.24GlobeNewswireRoche’s fenebrutinib demonstrated near-complete suppression of disease activity and disability progression for up to 48 weeks in patients with relapsing multiple sclerosis

27.08.24GlobeNewswireRoche’s PiaSky approved in the EU as the first monthly subcutaneous treatment for people with PNH

20.08.24GlobeNewswireRoche responds to WHO’s declaration of a global health emergency due to the ongoing mpox outbreak

30.07.24GlobeNewswireEuropean Commission approves Roche’s Vabysmo for treatment of retinal vein occlusion (RVO)

29.07.24GlobeNewswireRoche closes acquisition of LumiraDx’s Point of Care technology to expand access to diagnostic testing in primary care

25.07.24GlobeNewswire[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 5% (CER) in first half of 2024; strong growth in second quarter – full-year earnings outlook raised

25.07.24GlobeNewswire[Ad-hoc-Mitteilung gemäss Art. 53 KR] Verkäufe der Roche-Gruppe steigen im ersten Halbjahr 2024 um 5% (CER); starkes Wachstum im zweiten Quartal – Gewinnprognose für das Gesamtjahr erhöht

18.07.24GlobeNewswireNew data for Roche’s Susvimo demonstrates sustained efficacy in two serious diabetic eye conditions

17.07.24GlobeNewswireRoche’s Vabysmo showed extended durability, continued efficacy and a consistent safety profile in long-term diabetic macular edema (DME) study

17.07.24GlobeNewswire[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment of people with obesity

10.07.24PR NewswireRemix Therapeutics™ Attains Near-Term Milestone from Roche Collaboration

09.07.24GlobeNewswireRoche receives CE Mark for its AI-enabled continuous glucose monitoring solution offering critical predictions to people living with diabetes

08.07.24GlobeNewswireRoche to reintroduce Susvimo in the US for people with neovascular age-related macular degeneration (nAMD)

05.07.24GlobeNewswireFDA approves Roche’s Vabysmo prefilled syringe (PFS) for three leading causes of vision loss

04.07.24GlobeNewswire[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on phase II/III SKYSCRAPER-06 study in metastatic non-squamous non-small cell lung cancer

28.06.24GlobeNewswireRoche’s Vabysmo gets CHMP recommendation for third indication retinal vein occlusion (RVO)

28.06.24GlobeNewswireCHMP recommends EU approval of Roche’s PiaSky for people with PNH, a rare, life-threatening blood condition

27.06.24GlobeNewswireRoche expands access to cervical cancer screening tools with two new WHO prequalification designations, including HPV self-collection

25.06.24GlobeNewswireRoche’s OCREVUS subcutaneous administration approved by European Commission, as first and only twice-a-year injection for relapsing and primary progressive multiple sclerosis

24.06.24GlobeNewswireRoche launches new analytical units for cobas® pro integrated solutions delivering greater efficiency and capacity to laboratories

20.06.24GlobeNewswireRoche launches new highly-sensitive test to more easily diagnose patients who may have B-cell lymphoma

18.06.24PR NewswireRoche receives FDA clearance on its digital pathology solution for diagnostic use

15.06.24GlobeNewswireRoche’s Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell lymphoma

10.06.24GlobeNewswireRoche four-in-one molecular test for SARS-CoV-2, Influenza A/B viruses and RSV receives U.S. FDA Emergency Use Authorization

10.06.24GlobeNewswireEuropean Commission approves Roche’s Alecensa as the first and only targeted adjuvant treatment for people with ALK-positive early-stage lung cancer

07.06.24GlobeNewswireFive-year data for Roche’s Evrysdi show the majority of treated children with a severe form of spinal muscular atrophy (SMA) achieved or maintained the ability to sit, stand or walk

29.05.24GlobeNewswireFDA grants Priority Review to Roche’s inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation

27.05.24PR NewswireRoche and Hitachi High-Tech extend their 46-year partnership, paving the way for further breakthroughs in diagnostic testing

Roche News

Roche News: auf dieser Seite finden Sie alle Roche News und Nachrichten zur Roche Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Roche News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Roche News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.